---
title: "Wat kost uw transactie aan vergoedingen?"
description: "Vergoedingen bij Amerikaanse transacties, geen koopprijzen: advies, juridisch, beursgang, plaatsing en Chapter 11."
site: Deal Cost Index
content_updated: 2026-10-29
license: CC BY 4.0
html: https://dealcostindex.com/index-nl.html
---
Vergoedingen bij Amerikaanse transacties

# Wat kost uw transactie aan vergoedingen?

De Deal Cost Index meet wat ondernemingen betalen aan zakenbanken, advocaten, accountants, begeleidende banken en dataroom-aanbieders om een transactie af te ronden. Koopprijzen, waarderingsmultiples en financieringskosten horen niet bij deze site.

Vul uw transactie in om de kosten voor advies, juridisch werk, accountancy, due diligence en dataroom te projecteren. Elke post is geprojecteerd uit openbare publicaties, gepubliceerde enquêtes of prijslijsten van aanbieders, met een link naar de bron.

Gebouwd op

660

fusiedocumenten en openbare biedingen

502

prospectussen van beursgangen

52,571

private rondes (Form D)

47

Chapter 11-procedures

132

gepubliceerde enquêtewaarden

Stukken bij de SEC en bij Amerikaanse faillissementsrechtbanken, 2023–2026.

Geprojecteerde vergoedingen

$4.4M–$10.7M — Verkoop (verkoperszijde) · $250M

- M&A advisor fees 93%

- Deal counsel 5%

- Sell-side quality of earnings 2%

- Virtual data room <1%

Som van de 4 posten die als meegerekend zijn gemarkeerd, geprojecteerd uit openbare publicaties, gepubliceerde enquêtes en prijslijsten van aanbieders. Posten in grijs staan er ter referentie en worden niet opgeteld.

Een projectie, geen prijsopgave. Deze bandbreedte is afgeleid uit openbare informatie over andere transacties. De vergoedingen bij uw transactie hangen af van de feiten, van de kantoren die u inschakelt en van wat u onderhandelt. Niets hiervan is financieel, juridisch, fiscaal of beleggingsadvies. [Voorwaarden en disclaimer](https://dealcostindex.com/terms.html)

continues to $25M →

$0$9.16M

| Post | Middelste helft en mediaan | Bandbreedte |
|---|---|---|
| M&A advisor fees (all target-side advisors)Filed 58 recordsTotal target-side advisor fees as a share of deal value in 58 disclosed deals ($125M–$500M): median 2.60%, middle half 1.73%–3.66%. Public-target deals; private deals of this size usually pay at least as much. |  | $4.32M–$9.16Mmediaan $6.5M |
| Fairness opinion fee (part of the advisor fee)Filed 45 records · Alleen ter referentiePortion payable on delivery of the opinion, from the same filings. Usually credited against the success fee. |  | $1M–$1.75Mmediaan $1M |
| Lehman / Double Lehman formulaFormula · Alleen ter referentie5-4-3-2-1 and 10-8-6-4-2 schedules applied to $250M. Shown for reference; this is not an observed fee. |  | $2.6M–$5.2Mmediaan $3.9M |
| Monthly retainerSurvey · Alleen ter referentie$5,000–$10K a month is the most common retainer, over 6 months; most advisors credit it against the success fee. [Firmex 2025](https://4804905.fs1.hubspotusercontent-na1.net/hubfs/4804905/Firmex-MAFeeGuide-Global-25.pdf) |  | $30K–$60Kmediaan $45K |
| Deal counselSurveyExternal legal spend per M&A deal reported by US private equity firms (average $353K, range $50K–$1M, 2020 data). Large-firm partners in New York averaged $1,972/hour in H1 2025. [Apperio 2020](https://www.persuit.com/learn/typical-manda-deals-cost-us-private-equity-353k-in-legal-spend-and-other-outside-counsel-statistics-from-us-based-pe-firms) [Wolters Kluwer ELM Solutions via B 2025](https://www.nasdaq.com/press-release/wolters-kluwer-study-sets-stage-2026-sharp-contrasts-regional-law-firm-rates-and) |  | $50K–$1Mmediaan $353K |
| Sell-side quality of earningsSurveyPublished price ranges for a >$150M deal: boutique providers $25K–$50K, buy-side QoE $150K–$400K, sell-side priced 10–30% higher. [BD Emerson 2026](https://www.bdemerson.com/article/quality-of-earnings-report-cost) [Bedrock Quality of Earnings 2026](https://www.bedrockqoe.com/insights/quality-of-earnings-report-cost) |  | $25K–$520Kmediaan $114K |
| Virtual data roomList price 8 recordsMiddle half of list-price totals from 8 vendors whose published plans cover 20 GB and 2 admins for 6 months, billed monthly where offered. Plans are priced for the months billed, not the months used. [How data room totals are calculated](https://dealcostindex.com/vdr.html#billing-basis) |  | $2,499–$18Kmediaan $3,764 |
| R&W insuranceSurvey · Alleen ter referentieLimit 10% of EV ($25M) × rate on line 2–3.5% (Q4 2025 average 3.23%), plus underwriting fee and up to 6% surplus lines tax. [Gallagher 2025](https://www.ajg.com/-/media/files/gallagher/us/news-and-insights/2025/transactional-risk-2025-review-and-2026-outlook.pdf) [Vanbridge 2024](https://www.vanbridge.com/wp-content/uploads/2024/02/2024-Vanbridge-Reps-and-Warranties-Reference-Guide.pdf) [Vanbridge 2024](https://www.vanbridge.com/wp-content/uploads/2024/02/2024-Vanbridge-Reps-and-Warranties-Reference-Guide.pdf) Typically paid by the buyer; sometimes split. |  | $535K–$978Kmediaan $850K |
| Escrow held back (not a fee)Survey · Alleen ter referentieCash withheld from proceeds, typically released after ~12 months: median 2.8% of deal value with R&W insurance, 10% without. [DealLawyers.com 2026](https://www.deallawyers.com/blog/2026/04/study-private-target-deal-terms-10.html) [SRS Acquiom 2025](https://www.srsacquiom.com/our-insights/ma-deals/) Typically paid by the buyer; sometimes split. |  | $7M–$25Mmediaan $7M |
| Totaal |  | $4.4M–$10.7MSom van de medianen $6.97M |

De onderbouwing per post, de notities eronder en de tabellen met de gebruikte vergelijkbare transacties blijven Engels: ze citeren en parafraseren de stukken waaruit ze komen, en citaten worden op deze site niet vertaald. De Engelse versie van deze pagina is bindend.

## Public-company deals used ($125M–$500M)

Each fee is taken from the filing; hover over a fee to see the sentence it comes from. Deal values marked “computed” are the cash price per share multiplied by shares outstanding.

| Target | Deal value | Advisor | Fee | % of value | Source |
|---|---|---|---|---|---|
| Greenbacker Renewable Energy | $375M — stated | Wells Fargo Securities | $7M | 1.87% | [DEFM14A Oct 2026](https://www.sec.gov/Archives/edgar/data/1563922/000175392626001969/g085989_defm14a.htm) |
| Nathans Famous, Inc. | $418M — computed | Jefferies | $9.6M | 2.30% | [DEFM14A Sep 2026](https://www.sec.gov/Archives/edgar/data/69733/000110465926110393/tm267612-2_defm14a.htm) |
| Luxfer Holdings PLC | $465M — computed | Deutsche Bank | $8M | 1.72% | [DEFM14A Sep 2026](https://www.sec.gov/Archives/edgar/data/1096056/000207709626000260/ea0303080-02.htm) |
| AstroNova, Inc. — acquired by Arcline | $225M — computed | Rockefeller | $4.2M | 1.87% | [DEFM14A Jul 2026](https://www.sec.gov/Archives/edgar/data/8146/000119312526326441/d140981ddefm14a.htm) |
| Simulations Plus, Inc. | $375M — stated | Morgan Stanley | $11M | 2.93% | [DEFM14A Jul 2026](https://www.sec.gov/Archives/edgar/data/1023459/000102345926000051/defm14a.htm) |
| Open Lending Corp — acquired by Anv | $236M — computed | FT | $8.7M | 3.68% | [SC 14D9 Jun 2026](https://www.sec.gov/Archives/edgar/data/1806201/000119312526286952/d140679dsc14d9.htm) |
| Cross Country Healthcare Inc. | $428M — computed | BofA Securities | $6.12M | 1.43% | [DEFM14A Jun 2026](https://www.sec.gov/Archives/edgar/data/1141103/000114036126025249/ny20073866x2_defm14a.htm) |
| XOMA Royalty Corp | $489M — computed | Leerink Partners | $18.4M | 3.76% | [DEFM14A Jun 2026](https://www.sec.gov/Archives/edgar/data/791908/000119312526266069/d137792ddefm14a.htm) |
| Sun Country Airlines Holdings, Inc. — acquired by Allegiant | $218M — computed | Goldman Sachs | $22.6M | 10.36% | [DEFM14A Mar 2026](https://www.sec.gov/Archives/edgar/data/1743907/000114036126012383/ny20068391x1_defm14a.htm) |
| Calavo Growers, Inc. — acquired by Mission Produce | $486M — stated | Jefferies | $12.5M | 2.57% | [DEFM14A Mar 2026](https://www.sec.gov/Archives/edgar/data/1133470/000119312526117814/d15959ddefm14a.htm) |
| Diamond Hill Investment Group, Inc. — acquired by First Eagle | $430M — computed | Broadhaven | $7M | 1.63% | [DEFM14A Jan 2026](https://www.sec.gov/Archives/edgar/data/909108/000114036126002681/ny20061565x2_defm14a.htm) |
| Crawford United Corporation — acquired by Spx | $300M — stated | Lake StreetStout | $2.4M | 0.80% | [DEFM14A Jan 2026](https://www.sec.gov/Archives/edgar/data/47307/000143774926000391/crawa20260103_defm14a.htm) |
| TrueCar, Inc. | $227M — computed | Morgan Stanley | $12.5M | 5.51% | [DEFM14A Nov 2025](https://www.sec.gov/Archives/edgar/data/1327318/000110465925115451/tm2528639-6_defm14a.htm) |
| WideOpenWest, Inc. — acquired by DigitalBridge and Crestview | $290M — stated | Centerview Partners | $19.4M | 6.69% | [DEFM14A Oct 2025](https://www.sec.gov/Archives/edgar/data/1701051/000110465925102255/tm2523589-7_defm14a.htm) |
| scPharmaceuticals Inc. | $285M — computed | Leerink Partners | $8.8M | 3.09% | [SC 14D9 Sep 2025](https://www.sec.gov/Archives/edgar/data/1604950/000119312525225023/d846289dsc14d9a.htm) |
| Potbelly Corporation — acquired by RaceTrac | $409M — computed | Piper Sandler | $6.9M | 1.69% | [SC 14D9 Sep 2025](https://www.sec.gov/Archives/edgar/data/1195734/000119312525213634/d936677dsc14d9.htm) |
| scPharmaceuticals Inc. | $285M — computed | Leerink Partners | $8.8M | 3.09% | [SC 14D9 Sep 2025](https://www.sec.gov/Archives/edgar/data/1604950/000119312525198383/d152074dsc14d9.htm) |
| Y-mAbs Therapeutics, Inc. — acquired by Serb | $354M — computed | Centerview Partners | $9.1M | 2.57% | [SC 14D9 Aug 2025](https://www.sec.gov/Archives/edgar/data/1722964/000110465925079582/tm2523645-2_sc14d9.htm) |
| DallasNews Corp | $150M — computed | J.P. Morgan | $5M | 3.34% | [DEFM14A Aug 2025](https://www.sec.gov/Archives/edgar/data/1413898/000119312525181885/d24897ddefm14a.htm) |
| iTeos Therapeutics, Inc. | $385M — computed | TD Cowen | $9.5M | 2.47% | [SC 14D9 Aug 2025](https://www.sec.gov/Archives/edgar/data/1808865/000119312525170952/d854787dsc14d9.htm) |
| CARGO Therapeutics, Inc. | $202M — computed | TD Cowen | $4.3M | 2.13% | [SC 14D9 Jul 2025](https://www.sec.gov/Archives/edgar/data/1966494/000119312525163464/d78481dsc14d9.htm) |
| Sage Therapeutics, Inc. — acquired by Supernus Pharmaceuticals | $452M — computed | Goldman Sachs | $14.7M | 3.25% | [SC 14D9 Jul 2025](https://www.sec.gov/Archives/edgar/data/1597553/000119312525155020/d63256dsc14d9.htm) |
| Verve Therapeutics, Inc. — acquired by Eli Lilly and Company | $267M — computed | Centerview PartnersGuggenheim Securities | $33.7M | 12.60% | [SC 14D9 Jun 2025](https://www.sec.gov/Archives/edgar/data/1840574/000119312525146127/d917975dsc14d9.htm) |
| PHX Minerals Inc. — acquired by WhiteHawk Energy | $162M — computed | RBCCMIntrepid | $4.25M | 2.62% | [SC 14D9 May 2025](https://www.sec.gov/Archives/edgar/data/315131/000110465925051830/tm2515778-1_sc14d9.htm) |
| Checkpoint Therapeutics, Inc. — acquired by Sun Pharmaceutical Industries (LW Securities engaged) | $475M — computed | Kroll | $400K | 0.08% | [DEFM14A Apr 2025](https://www.sec.gov/Archives/edgar/data/1651407/000110465925038082/tm252489-4_defm14a.htm) |
| Akoya Biosciences, Inc. — acquired by Quanterix Corporation | $199M — computed | Perella Weinberg Partners | $3.5M | 1.76% | [DEFM14A Apr 2025](https://www.sec.gov/Archives/edgar/data/1711933/000110465925035134/tm2510802-1_defm14a.htm) |
| 2seventy bio, Inc. — acquired by Bristol-Myers Squibb | $262M — computed | Goldman Sachs | $8.58M | 3.28% | [SC 14D9 Apr 2025](https://www.sec.gov/Archives/edgar/data/1860782/000114036125013644/ny20046860x1_sc14d9.htm) |
| Logility Supply Chain Solutions, Inc — acquired by Aptean | $478M — computed | Lazard | $9.8M | 2.05% | [DEFM14A Mar 2025](https://www.sec.gov/Archives/edgar/data/713425/000114036125006872/ny20042527x2_defm14a.htm) |
| Poseida Therapeutics, Inc. | $390M — computed | Centerview Partners | $25.5M | 6.54% | [SC 14D9 Dec 2024](https://www.sec.gov/Archives/edgar/data/1661460/000119312524286056/d871087dsc14d9a.htm) |
| Poseida Therapeutics, Inc. — acquired by Roche | $390M — computed | Centerview Partners | $25.5M | 6.54% | [SC 14D9 Dec 2024](https://www.sec.gov/Archives/edgar/data/1661460/000119312524273550/d901928dsc14d9.htm) |
| Universal Stainless & Alloy Products Inc | $456M — stated | TD Cowen | $8.1M | 1.78% | [DEFM14A Nov 2024](https://www.sec.gov/Archives/edgar/data/931584/000119312524267249/d842335ddefm14a.htm) |
| ARC Document Solutions, Inc. | $162M — stated | William Blair | $1M | 0.62% | [DEFM14A Oct 2024](https://www.sec.gov/Archives/edgar/data/1305168/000114036124043469/ny20035563x8_defm14a.htm) |
| Iteris, Inc. — acquired by Almaviva | $308M — computed | Morgan Stanley | $10.5M | 3.41% | [DEFM14A Sep 2024](https://www.sec.gov/Archives/edgar/data/350868/000114036124041589/ny20034699x2_defm14a.htm) |
| G1 Therapeutics, Inc. | $259M — computed | Centerview PartnersGuggenheim Securities | $16.9M | 6.54% | [SC 14D9 Aug 2024](https://www.sec.gov/Archives/edgar/data/1560241/000119312524203615/d856692dsc14d9.htm) |
| Desktop Metal, Inc. | $349M — computed | Stifel | $4.2M | 1.20% | [DEFM14A Aug 2024](https://www.sec.gov/Archives/edgar/data/1754820/000110465924089909/tm2420443-3_defm14a.htm) |
| The Aaron's Company, Inc. — acquired by Iqv | $310M — computed | J.P. Morgan | $10.1M | 3.26% | [DEFM14A Aug 2024](https://www.sec.gov/Archives/edgar/data/1821393/000119312524199465/d816734ddefm14a.htm) |
| Alimera Sciences, Inc. | $498M — computed | Perella Weinberg PartnersCenterview Partners | $18M | 3.62% | [DEFM14A Aug 2024](https://www.sec.gov/Archives/edgar/data/1267602/000110465924087307/tm2419772-3_defm14a.htm) |
| SilverBow Resources, Inc. — acquired by Crescent | $391M — computed | BofA SecuritiesEvercore | $32M | 8.18% | [DEFM14A Jun 2024](https://www.sec.gov/Archives/edgar/data/351817/000162828024030396/silverbow-defm14a.htm) |
| Whole Earth Brands, Inc. — acquired by Sababa | $211M — computed | JefferiesCiti | $13M | 6.17% | [DEFM14A Jun 2024](https://www.sec.gov/Archives/edgar/data/1753706/000114036124031141/ny20024121x13_defm14a.htm) |
| Transphorm, Inc. — acquired by Renesas | $323M — computed | BofA Securities | $6.21M | 1.92% | [DEFM14A Mar 2024](https://www.sec.gov/Archives/edgar/data/1715768/000119312524058005/d585789ddefm14a.htm) |

Showing 40 of 58, most recent first. The full list is on the dataset page.

## De datasets

- [660Vergoedingen van M&A-adviseursFusiedocumenten en openbare biedingen, 2023–2026. Vergoedingen naar transactieomvang, niveau van het kantoor, sector en opdrachtgever, het deel dat bij closing verschuldigd is en een profiel van elke veelvoorkomende bank.](https://dealcostindex.com/ma-advisor-fees-nl.html)

- [288Juridische kostenKantoren bij beursgangen, fusies en Chapter 11-procedures: juridische kosten bij de beursgang, uurtarieven van partners en een profiel van elk veelvoorkomend kantoor.](https://dealcostindex.com/legal-fees-nl.html)

- [86AccountantskostenAccountants bij Amerikaanse beursgangen en de kosten die uitgevende instellingen uitsplitsen, prijzen voor quality of earnings-onderzoek en een profiel van elk veelvoorkomend accountantskantoor.](https://dealcostindex.com/accounting-fees-nl.html)

- [502Kosten van een beursgangDefinitieve prospectussen. Plaatsingsvergoeding en uitgesplitste juridische, accountants-, druk- en beurskosten.](https://dealcostindex.com/ipo-costs-nl.html)

- [52,571PlaatsingsvergoedingenPrivate rondes uit Form D-opgaven, 2023 Q1 tot 2026 Q3. Provisies en bemiddelingsvergoedingen naar omvang, instrument en sector.](https://dealcostindex.com/capital-raise-fees-nl.html)

- [47Vergoedingen in Chapter 11Rechtbankdossiers. Maandvergoedingen, herstructureringsvergoedingen en uurtarieven van de professionals van de schuldenaar.](https://dealcostindex.com/restructuring-fees-nl.html)

- [132Due diligence, verzekering en escrowGepubliceerde enquêtes en prijslijsten van kantoren voor kosten die stukken niet per transactie bekendmaken.](https://dealcostindex.com/diligence-insurance-nl.html)

- [25DataroomsLijstprijzen, schattingen van derden en vermelde certificeringen, berekend voor uw dataroom.](https://dealcostindex.com/vdr-nl.html)

- [639Overzicht van adviseursBanken, advocatenkantoren en accountants uit 27 openbare lijsten, de basis voor elk niveau in de rekenhulp.](https://dealcostindex.com/providers-nl.html)

## Verwijzen naar de index

Verwijs naar de gebruikte pagina als Deal Cost Index, “<paginatitel>”, dataversie 2026.10.3, met een link. De onderliggende gegevens staan onder [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/) en zijn als CSV te downloaden via de [methodologiepagina](https://dealcostindex.com/methodology-nl.html); elke regel houdt de link naar het stuk of de publicatie waaruit die komt.

Deal Cost Index. Data: CC BY 4.0.